LCA-AAV7

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLCA-AAV7

Drug Alias NameLeber's congenital amaurosis gene therapy (RegenX Biosciences)adeno-associated virus based vector-7 based gene therapy (RegenX Biosciences)RPE-65 gene therapy (RegenX Biosciences)LCA-AAV7

ClassificationBiologics

Mechanisms of ActionRetinoid isomerohydrolase stimulants

TargetsRetinoid isomerohydrolase

Therapy Area/IndicationsLeber Congenital Amaurosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRegenxbio Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRegenxbio Inc

Active IndicationsN/A

Inactive IndicationsLeber Congenital Amaurosis

Other Information

ATC CodeN/A